Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:Sarepta_Therapeutics
|
| gptkbp:effective_date |
not approved by FDA
|
| gptkbp:first_introduced |
gptkb:2016
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eteplirsen
|
| gptkbp:mechanism_of_action |
exon skipping
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:targets |
dystrophin gene
|
| gptkbp:type |
exon skipping therapy
|
| gptkbp:used_for |
gptkb:Duchenne_muscular_dystrophy
|
| gptkbp:bfsParent |
gptkb:Sarepta_Therapeutics
|
| gptkbp:bfsLayer |
5
|